SCHEMBL594359

SCHEMBL594359

CC(C)(C)OC(=O)C(N)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
ATM Q13315 1/20 0.45
KMT2A Q03164 3/20 0.44
AAK1 Q2M2I8 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AOC3 Q16853 1/20 0.41
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
RECQL P46063 1/20 0.40
LTA4H P09960 1/20 0.40
SLC7A5 Q01650 1/20 0.39
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30065221 1.00 L3MBTL1 (0.45) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL305032 1.00 L3MBTL1 (0.45) L3MBTL1ATMKMT2AAAK1CTSS
Hydrochloric Acid SCHEMBL304679 0.98 ATM (0.44) L3MBTL1ATMKMT2AAAK1CTSS
Hydrochloric Acid SCHEMBL595486 0.98 ATM (0.44) L3MBTL1ATMKMT2AAAK1CTSS
Hydrochloric Acid SCHEMBL628345 0.98 ATM (0.44) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL6606388 0.86 ATM (0.41) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL1925699 0.86 ATM (0.41) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL27636817 0.86 ATM (0.41) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL30745061 0.84 ALDH1A1 (0.44) L3MBTL1ATMKMT2ANPSR1CYP1A2
SCHEMBL506934 0.84 ANPEP (0.45) KMT2AAAK1CYP1A2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3642252-A1 LATENT CURING AGENT AND CURABLE POLYURETHANE COMPOSITION Sika Technology AG (CH) 2020-04-29 EP disclosed
WO-2020040293-A1 PRODUCTION METHOD FOR MESENCHYMAL STEM CELLS 株式会社ステムリム 2020-02-27 WO disclosed
CN-107857730-B A kind of fluorosulfonyl group-containing compound, wherein mesosome, preparation method and application 中国科学院上海有机化学研究所 2019-10-15 CN disclosed
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-27 US disclosed
EP-2928879-B1 PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARM SPA (IT) 2018-02-28 EP disclosed
EP-2928879-B1 PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARM SPA (IT) 2018-02-28 EP disclosed
EP-2970312-B1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2017-11-15 EP disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 US disclosed
CN-1656079-A Pyrazole compounds and pharmaceutical compositions containing the same EISAI CO LTD (JP) 2005-08-17 CN disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
CN-1481373-A 1,5-benzothiazepines compounds and its use as antilipemic agent 2004-03-10 CN disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed
CN-1238779-A Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis ELAN PHARM INC (US) 1999-12-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same BRD4, BRDT, BRD3 L3MBTL1 1160/4885ATM 1477/4885KMT2A 337/4885
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH L3MBTL1 3448/4885ATM 3616/4885KMT2A 4759/4885
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 L3MBTL1 1160/4885ATM 1477/4885KMT2A 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.